SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
-------------------------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 16, 2002
------------------
CYTOGEN CORPORATION
(Exact Name of Registrant as Specified in Charter)
Delaware 000-14879 222322400
--------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission File Number) (IRS Employer
of Incorporation) Identification No.)
650 College Road East, CN 5308, Suite 3100, Princeton, NJ 08540
--------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
(609) 750-8200
------------------------------------------------
(Registrant's telephone number, including area code)
600 College Road East, CN 5308, Princeton, NJ 08540
------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
Item 5. Other Events.
On September 16, 2002, Cytogen Corporation (the "Company") issued a press
release reporting the internal restructuring of the Company's AxCell Biosciences
subsidiary.
On September 17, 2002, the Company issued a joint press release with
Matritech Inc. announcing an agreement in principle to enter into a five year
agreement for the Company to be the sole United States distributor for
Matritech's NMP22(R) BladderChek(TM) test. Such arrangement is pending the
approval and execution of a final agreement by both parties.
Each such press release is attached hereto as Exhibit 99.1 and Exhibit
99.2, respectively, and each is incorporated herein by reference. The foregoing
description of each such press release is qualified in its entirety by reference
to each such respective document.
Item 7. Financial Statements, Pro Forma Financial Information
and Exhibits.
(c) Exhibits.
Exhibit No. Description
----------- -----------
99.1 Press release of the Company dated September 16, 2002
99.2 Press release of the Company dated September 17, 2002
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Cytogen Corporation
By: /s/ Lawrence R. Hoffman
-----------------------------------
Lawrence R. Hoffman,
Chief Financial Officer
Date: September 17, 2002